{"schema_version":"secwatch.filing_event.v1","accession":"0000856982-23-000039","form_type":"8-K","ticker":"MMSI","cik":"0000856982","company_name":"MERIT MEDICAL SYSTEMS INC","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.449059+00:00","generated_at":"2026-06-14T05:27:15.376654+00:00","sec_items":["1.01","2.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merit Medical acquires two product portfolios for $132.5M; updates 2023 guidance","bullets":["Acquired dialysis catheter portfolio & BioSentry system from AngioDynamics for $100M cash.","Acquired Surfacer Inside-Out Access Catheter System from Bluegrass Vascular for $32.5M cash.","Projects combined acquisitions to add ~$30M annual revenue; accretive to non-GAAP net income and EPS in first full year.","Reaffirms stand-alone FY2023 guidance; updated to include partial-year impact from acquisitions.","Extended CEO Fred Lampropoulos employment through 12/31/2025; base salary increased to $1,890,000."],"urls":{"canonical":"https://secwatch.observer/filing/0000856982-23-000039","json":"https://secwatch.observer/filing/0000856982-23-000039.json","markdown":"https://secwatch.observer/filing/0000856982-23-000039.md","text":"https://secwatch.observer/filing/0000856982-23-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/0000856982-23-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/mmsi-20230608x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:27:15.376654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"727b34826069c67d78ca898259abc8bb2ea9a79f","claim":"MERIT MEDICAL SYSTEMS INC updated its full-year 2023 guidance (reaffirmed).","evidence_excerpt":"Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include partial-year impact from acquisitions","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/0000856982-23-000039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"04aa2c835ab61b5761bb0bb88427c8797f6a117c","claim":"MERIT MEDICAL SYSTEMS INC entered into Purchase Agreement with AngioDynamics, Inc. valued at $100 million (effective 2023-06-08).","evidence_excerpt":"On June 8, 2023, Merit entered into an Asset Purchase Agreement (the “Purchase Agreement”) with AngioDynamics, Inc., a Delaware corporation (“AngioDynamics”), pursuant to which Merit acquired a portfolio of dialysis catheter products, including various assets related thereto, and the BioSentry ® Biopsy Tract Sealant System from AngioDynamics (collectively, the “Acquisition”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/856982/000085698223000039/0000856982-23-000039-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"AngioDynamics, Inc."},{"label":"Value","value":"$100 million"},{"label":"Effective","value":"2023-06-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}